Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: May 30, 2023

VIBATIV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


DrugPatentWatch® Generic Entry Outlook for Vibativ

Vibativ was eligible for patent challenges on September 11, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for VIBATIV
Drug patent expirations by year for VIBATIV
Drug Prices for VIBATIV

See drug prices for VIBATIV

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIBATIV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cumberland Pharmaceuticals, Inc.Phase 4
Joseph KutiPhase 4
Theravance Biopharma, US, Inc.Phase 4

See all VIBATIV clinical trials

Pharmacology for VIBATIV

US Patents and Regulatory Information for VIBATIV

VIBATIV is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIBATIV is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIBATIV

Glycopeptide phosphonate derivatives
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD FOR TREATING BACTERIAL INFECTION

Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Hydrochloride salts of a glycopeptide phosphonate derivative
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIBATIV

International Patents for VIBATIV

When does loss-of-exclusivity occur for VIBATIV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 04285924
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0415853
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 43009
Estimated Expiration: ⤷  Try a Trial

Patent: 26967
Estimated Expiration: ⤷  Try a Trial

China

Patent: 71253
Estimated Expiration: ⤷  Try a Trial

Patent: 0417661
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 13773
Estimated Expiration: ⤷  Try a Trial

Patent: 15276
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 78201
Estimated Expiration: ⤷  Try a Trial

Patent: 95251
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 78201
Estimated Expiration: ⤷  Try a Trial

Patent: 95251
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 93516
Estimated Expiration: ⤷  Try a Trial

Patent: 71030
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 26769
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 69478
Estimated Expiration: ⤷  Try a Trial

Patent: 07534630
Estimated Expiration: ⤷  Try a Trial

Patent: 11016820
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 06004336
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 78201
Estimated Expiration: ⤷  Try a Trial

Patent: 95251
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 78201
Estimated Expiration: ⤷  Try a Trial

Patent: 95251
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 78201
Estimated Expiration: ⤷  Try a Trial

Patent: 95251
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1166250
Estimated Expiration: ⤷  Try a Trial

Patent: 060094082
Estimated Expiration: ⤷  Try a Trial

Patent: 120037025
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 00483
Estimated Expiration: ⤷  Try a Trial

Patent: 77268
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 42312
Estimated Expiration: ⤷  Try a Trial

Patent: 0528473
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIBATIV around the world.

Country Patent Number Title Estimated Expiration
Canada 2408008 COMPOSITIONS PHARMACEUTIQUES CONTENANT UN ANTIBIOTIQUE GLYCOPEPTIDIQUE ET UNE CYCLODEXTRINE (PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A CYCLODEXTRIN) ⤷  Try a Trial
Denmark 2495251 ⤷  Try a Trial
South Korea 101166250 ⤷  Try a Trial
South Africa 200209419 Glycopeptide phosphonate derivatives. ⤷  Try a Trial
Australia 5929801 ⤷  Try a Trial
European Patent Office 1278549 COMPOSITION CONTENANT UNE CYCLODEXTRINE ET UN ANTIBIOTIQUE GYLCOPEPTIDIQUE (COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC) ⤷  Try a Trial
Cyprus 1113773 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIBATIV

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1292612 SPC/GB11/056 United Kingdom ⤷  Try a Trial PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
1292612 PA2012002 Lithuania ⤷  Try a Trial PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612 132012902025885 Italy ⤷  Try a Trial PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902
1292612 PA2012002,C1292612 Lithuania ⤷  Try a Trial PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
1292612 C300507 Netherlands ⤷  Try a Trial PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
1292612 2011C/045 Belgium ⤷  Try a Trial PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902
1292612 C 2012 002 Romania ⤷  Try a Trial PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Johnson and Johnson
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.